TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial fo… Read more
TWi Biotechnology, Inc. (6610) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.251x
Based on the latest financial reports, TWi Biotechnology, Inc. (6610) has a cash flow conversion efficiency ratio of -0.251x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-67.41 Million) by net assets (NT$268.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TWi Biotechnology, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how TWi Biotechnology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TWi Biotechnology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TWi Biotechnology, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Century Premium Developments Limited
PINK:PCPDF
|
-1.695x |
|
ENGIE Eps S.A
F:8XE
|
-0.075x |
|
ELUON Corporation
KQ:065440
|
-0.017x |
|
Ebebek Magazacilik Anonim Sirketi
IS:EBEBK
|
0.354x |
|
Acarix AB (publ)
OTCQB:ACIXF
|
-0.186x |
|
Mohenz.Co.Ltd
KQ:006920
|
0.017x |
|
Benfica
LS:SLBEN
|
-0.164x |
|
Wheels Up Experience Inc
NYSE:UP
|
0.099x |
Annual Cash Flow Conversion Efficiency for TWi Biotechnology, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of TWi Biotechnology, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$175.85 Million | NT$-155.41 Million | -0.884x | -124.57% |
| 2023-12-31 | NT$341.04 Million | NT$-134.22 Million | -0.394x | -34.53% |
| 2022-12-31 | NT$205.92 Million | NT$-60.24 Million | -0.293x | -136.68% |
| 2021-12-31 | NT$278.80 Million | NT$-34.46 Million | -0.124x | +41.91% |
| 2020-12-31 | NT$294.11 Million | NT$-62.58 Million | -0.213x | +7.82% |
| 2019-12-31 | NT$423.91 Million | NT$-97.85 Million | -0.231x | -- |